216 related articles for article (PubMed ID: 10550141)
1. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C; Kollmannsberger C; Meisner C; Harstrick A; Beyer J; Metzner B; Hartmann JT; Schmoll HJ; Einhorn L; Kanz L; Nichols C
J Clin Oncol; 1999 Nov; 17(11):3450-6. PubMed ID: 10550141
[TBL] [Abstract][Full Text] [Related]
2. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial.
Hinton S; Catalano PJ; Einhorn LH; Nichols CR; David Crawford E; Vogelzang N; Trump D; Loehrer PJ
Cancer; 2003 Apr; 97(8):1869-75. PubMed ID: 12673712
[TBL] [Abstract][Full Text] [Related]
4. Long-term results of first-line sequential high-dose carboplatin, etoposide and ifosfamide chemotherapy with peripheral blood stem cell support for patients with advanced testicular germ cell tumor.
Miki T; Mizutani Y; Akaza H; Ozono S; Tsukamoto T; Terachi T; Naito K; Nonomura N; Hara I; Yoshida O;
Int J Urol; 2007 Jan; 14(1):54-9. PubMed ID: 17199861
[TBL] [Abstract][Full Text] [Related]
5. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
Tscherry G; Jacky E; Jost LM; Stahel RA
Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
[TBL] [Abstract][Full Text] [Related]
6. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.
Kaye SB; Mead GM; Fossa S; Cullen M; deWit R; Bodrogi I; van Groeningen C; Sylvester R; Collette L; Stenning S; De Prijck L; Lallemand E; deMulder P
J Clin Oncol; 1998 Feb; 16(2):692-701. PubMed ID: 9469359
[TBL] [Abstract][Full Text] [Related]
7. First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial.
Bokemeyer C; Schleucher N; Metzner B; Thomas M; Rick O; Schmoll HJ; Kollmannsberger C; Boehlke I; Kanz L; Hartmann JT
Br J Cancer; 2003 Jul; 89(1):29-35. PubMed ID: 12838296
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group.
Hartmann JT; Gauler T; Metzner B; Gerl A; Casper J; Rick O; Horger M; Schleicher J; Derigs G; Mayer-Steinacker R; Beyer J; Kuczyk MA; Bokemeyer C;
J Clin Oncol; 2007 Dec; 25(36):5742-7. PubMed ID: 18089869
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy followed by hematological support: experience in the treatment of germ cell tumors.
Pico JL; Fadel E; Ibrahim A; Bourhis JH; Droz JP
Bull Cancer; 1995; 82 Suppl 1():56s-60s. PubMed ID: 7542945
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors.
Bokemeyer C; Köhrmann O; Tischler J; Weissbach L; Räth U; Haupt A; Schöffski P; Harstrick A; Schmoll HJ
Ann Oncol; 1996 Dec; 7(10):1015-21. PubMed ID: 9037359
[TBL] [Abstract][Full Text] [Related]
11. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
12. Drug dose delivery and treatment outcome relationship in standard bleomycin, etoposide and cisplatin combination chemotherapy in nonseminomatous germ cell tumor patients.
Gutierrez-Delgado F; Titov DA; Tjulandin SA; Garin AM
Neoplasma; 1999; 46(3):190-5. PubMed ID: 10613596
[TBL] [Abstract][Full Text] [Related]
13. Analysis of salvage treatments for germ cell cancer patients who have relapsed after primary high-dose chemotherapy plus autologous stem cell support.
Kollmannsberger C; Schleucher N; Rick O; Metzner B; Hartmann JT; Schöffski P; Beyer J; Casper J; Sosada M; Schmoll HJ; Böhlke I; Meisner C; Kanz L; Bokemeyer C
Eur J Cancer; 2003 Apr; 39(6):775-82. PubMed ID: 12651203
[TBL] [Abstract][Full Text] [Related]
14. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Bajorin DF; Bosl GJ; Lyn P; Vlamis V
J Clin Oncol; 1997 Jul; 15(7):2546-52. PubMed ID: 9215823
[TBL] [Abstract][Full Text] [Related]
15. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients.
De Giorgi U; Rosti G; Papiani G; Marangolo M
Haematologica; 2002 Jan; 87(1):95-104. PubMed ID: 11801470
[TBL] [Abstract][Full Text] [Related]
16. [High dose chemotherapy with autologous stem cell support in the treatment of germ cell tumors: experience of the centre Léon-Bérard between 1982 and 1996].
Fléchon A; Biron P; Philip I; Blay JY; Droz JP
Bull Cancer; 1999 Apr; 86(4):391-9. PubMed ID: 10341344
[TBL] [Abstract][Full Text] [Related]
17. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
18. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival.
McCaffrey JA; Mazumdar M; Bajorin DF; Bosl GJ; Vlamis V; Motzer RJ
J Clin Oncol; 1997 Jul; 15(7):2559-63. PubMed ID: 9215825
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
